{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:15:38Z","timestamp":1784114138434,"version":"3.55.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:00:00Z","timestamp":1611360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T00:00:00Z","timestamp":1611360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Research, Development and Innovation Office (NKFIH) of Hungary","award":["K134939"],"award-info":[{"award-number":["K134939"]}]},{"name":"Ministry for Innovation and Technology, Hungary","award":["2020-4.1.1.-TKP2020"],"award-info":[{"award-number":["2020-4.1.1.-TKP2020"]}]},{"name":"National Research, Development and Innovation Fund of Hungary","award":["NVKP_16-1-2016-0017"],"award-info":[{"award-number":["NVKP_16-1-2016-0017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aims\/hypothesis<\/jats:title>\n                <jats:p>Large cardiovascular outcome trials demonstrated that the cardioprotective effects of sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors might reach beyond glucose-lowering action. In this meta-analysis, we sought to evaluate the potential infarct size-modulating effect of SGLT2 inhibitors in preclinical studies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this preregistered meta-analysis (PROSPERO: CRD42020189124), we included placebo-controlled, interventional studies of small and large animal models of myocardial ischaemia\u2013reperfusion injury, testing the effect of SGLT2 inhibitor treatment on myocardial infarct size (percentage of area at risk or total area). Standardised mean differences (SMDs) were calculated and pooled using random-effects method. We evaluated heterogeneity by computing <jats:italic>\u03a4<\/jats:italic><jats:sup>2<\/jats:sup> and <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup> values. Meta-regression was performed to explore prespecified subgroup differences according to experimental protocols and their contribution to heterogeneity was assessed (pseudo-<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup> values).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified ten eligible publications, reporting 16 independent controlled comparisons on a total of 224 animals. Treatment with SGLT2 inhibitor significantly reduced myocardial infarct size compared with placebo (SMD\u2009=\u2009\u22121.30 [95% CI \u22121.79, \u22120.81], <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.00001), referring to a 33% [95% CI 20%, 47%] difference. Heterogeneity was moderate (<jats:italic>\u03a4<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u20090.58, <jats:italic>I<\/jats:italic><jats:sup>2<\/jats:sup>\u00a0=\u200960%). SGLT2 inhibitors were only effective when administered to the intact organ system, but not to isolated hearts (<jats:italic>p<\/jats:italic> interaction &lt;0.001, adjusted pseudo-<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200947%). While acute administration significantly reduced infarct size, chronic treatment was superior (<jats:italic>p<\/jats:italic> interaction &lt;0.001, adjusted pseudo-<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200985%). The medications significantly reduced infarct size in both diabetic and non-diabetic animals, favouring the former (<jats:italic>p<\/jats:italic> interaction\u2009=\u20090.030, adjusted pseudo-<jats:italic>R<\/jats:italic><jats:sup>2<\/jats:sup>\u2009=\u200912%). Treatment was equally effective in rats and mice, as well as in a porcine model. Individual study quality scores were not related to effect estimates (<jats:italic>p<\/jats:italic>\u2009=\u20090.33). The overall effect estimate remained large even after adjusting for severe forms of publication bias.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions\/interpretation<\/jats:title>\n                <jats:p>The glucose-lowering SGLT2 inhibitors reduce myocardial infarct size in animal models independent of diabetes. Future in vivo studies should focus on clinical translation by exploring whether SGLT2 inhibitors limit infarct size in animals with relevant comorbidities, on top of loading doses of antiplatelet agents. Mechanistic studies should elucidate the potential relationship between the infarct size-lowering effect of SGLT2 inhibitors and the intact organ system.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00125-020-05359-2","type":"journal-article","created":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T03:02:52Z","timestamp":1611370972000},"page":"737-748","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Sodium\u2013glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia\u2013reperfusion injury: a meta-analysis"],"prefix":"10.1007","volume":"64","author":[{"given":"Alex Ali","family":"Sayour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csilla","family":"Celeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Ol\u00e1h","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mih\u00e1ly","family":"Ruppert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Merkely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"Radovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,23]]},"reference":[{"issue":"4","key":"5359_CR1","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E (2020) Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol 75(4):422\u2013434. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.031","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"5359_CR2","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373(22):2117\u20132128. https:\/\/doi.org\/10.1056\/NEJMoa1504720","journal-title":"N Engl J Med"},{"issue":"7","key":"5359_CR3","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"issue":"4","key":"5359_CR4","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"issue":"24","key":"5359_CR5","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"issue":"3","key":"5359_CR6","doi-asserted-by":"publisher","first-page":"e014908","DOI":"10.1161\/JAHA.119.014908","volume":"9","author":"C Arnott","year":"2020","unstructured":"Arnott C, Li Q, Kang A et al (2020) Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc 9(3):e014908. https:\/\/doi.org\/10.1161\/JAHA.119.014908","journal-title":"J Am Heart Assoc"},{"issue":"18","key":"5359_CR7","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","volume":"140","author":"ME Nassif","year":"2019","unstructured":"Nassif ME, Windsor SL, Tang F et al (2019) Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial. Circulation 140(18):1463\u20131476. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.042929","journal-title":"Circulation"},{"issue":"21","key":"5359_CR8","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"issue":"15","key":"5359_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"1383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 1383(15):1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"issue":"1","key":"5359_CR10","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1172\/JCI62874","volume":"123","author":"DJ Hausenloy","year":"2013","unstructured":"Hausenloy DJ, Yellon DM (2013) Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 123(1):92\u2013100. https:\/\/doi.org\/10.1172\/JCI62874","journal-title":"J Clin Invest"},{"issue":"14","key":"5359_CR11","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.jacc.2016.01.069","volume":"67","author":"GW Stone","year":"2016","unstructured":"Stone GW, Selker HP, Thiele H et al (2016) Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials. J Am Coll Cardiol 67(14):1674\u20131683. https:\/\/doi.org\/10.1016\/j.jacc.2016.01.069","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"5359_CR12","doi-asserted-by":"publisher","first-page":"165770","DOI":"10.1016\/j.bbadis.2020.165770","volume":"1866","author":"I Andreadou","year":"2020","unstructured":"Andreadou I, Bell RM, Botker HE, Zuurbier CJ (2020) SGLT2 inhibitors reduce infarct size in reperfused ischemic heart and improve cardiac function during ischemic episodes in preclinical models. Biochim Biophys Acta Mol basis Dis 1866(7):165770. https:\/\/doi.org\/10.1016\/j.bbadis.2020.165770","journal-title":"Biochim Biophys Acta Mol basis Dis"},{"key":"5359_CR13","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.3389\/fphys.2017.01077","volume":"8","author":"I Andreadou","year":"2017","unstructured":"Andreadou I, Efentakis P, Balafas E et al (2017) Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects. Front Physiol 8:1077. https:\/\/doi.org\/10.3389\/fphys.2017.01077","journal-title":"Front Physiol"},{"issue":"3","key":"5359_CR14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00395-019-0733-2","volume":"114","author":"HE Baker","year":"2019","unstructured":"Baker HE, Kiel AM, Luebbe ST et al (2019) Inhibition of sodium-glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization. Basic Res Cardiol 114(3):25. https:\/\/doi.org\/10.1007\/s00395-019-0733-2","journal-title":"Basic Res Cardiol"},{"issue":"1","key":"5359_CR15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12933-020-01066-9","volume":"19","author":"S Lahnwong","year":"2020","unstructured":"Lahnwong S, Palee S, Apaijai N et al (2020) Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia\/reperfusion injury. Cardiovasc Diabetol 19(1):91. https:\/\/doi.org\/10.1186\/s12933-020-01066-9","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"5359_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jacbts.2018.10.002","volume":"4","author":"VG Lim","year":"2019","unstructured":"Lim VG, Bell RM, Arjun S, Kolatsi-Joannou M, Long DA, Yellon DM (2019) SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart. JACC Basic Transl Sci 4(1):15\u201326. https:\/\/doi.org\/10.1016\/j.jacbts.2018.10.002","journal-title":"JACC Basic Transl Sci"},{"key":"5359_CR17","doi-asserted-by":"publisher","first-page":"110642","DOI":"10.1016\/j.mce.2019.110642","volume":"501","author":"Q Lu","year":"2020","unstructured":"Lu Q, Liu J, Li X et al (2020) Empagliflozin attenuates ischemia and reperfusion injury through LKB1\/AMPK signaling pathway. Mol Cell Endocrinol 501:110642. https:\/\/doi.org\/10.1016\/j.mce.2019.110642","journal-title":"Mol Cell Endocrinol"},{"key":"5359_CR18","doi-asserted-by":"publisher","unstructured":"Nikolaou PE, Efentakis P, Qourah FA et al (2020) Chronic Empaglifozin treatment reduces myocardial infarct size in non-diabetic mice through STAT-3 mediated protection on microvascular endothelial cells and reduction of oxidative stress. Antioxid Redox Signal. https:\/\/doi.org\/10.1089\/ars.2019.7923","DOI":"10.1089\/ars.2019.7923"},{"issue":"1","key":"5359_CR19","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","volume":"17","author":"AA Sayour","year":"2019","unstructured":"Sayour AA, Korkmaz-Icoz S, Loganathan S et al (2019) Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation. J Transl Med 17(1):127. https:\/\/doi.org\/10.1186\/s12967-019-1881-8","journal-title":"J Transl Med"},{"issue":"2","key":"5359_CR20","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1530\/JOE-17-0457","volume":"236","author":"P Tanajak","year":"2018","unstructured":"Tanajak P, Sa-Nguanmoo P, Sivasinprasasn S et al (2018) Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. J Endocrinol 236(2):69\u201384. https:\/\/doi.org\/10.1530\/JOE-17-0457","journal-title":"J Endocrinol"},{"key":"5359_CR21","doi-asserted-by":"publisher","unstructured":"Jespersen NR, Lassen TR, Hjortbak MV et al (2017) Sodium glucose transporter 2 (SGLT2) inhibition does not protect the myocardium from acute ischemic reperfusion injury but modulates post-ischemic mitochondrial function. Cardiovasc Pharmacol Open Access 6(2). https:\/\/doi.org\/10.4172\/2329-6607.1000210","DOI":"10.4172\/2329-6607.1000210"},{"issue":"10","key":"5359_CR22","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1093\/cvr\/cvz004","volume":"115","author":"L Uthman","year":"2019","unstructured":"Uthman L, Nederlof R, Eerbeek O et al (2019) Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts. Cardiovasc Res 115(10):1533\u20131545. https:\/\/doi.org\/10.1093\/cvr\/cvz004","journal-title":"Cardiovasc Res"},{"key":"5359_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijcard.2017.05.032","volume":"243","author":"A Di Franco","year":"2017","unstructured":"Di Franco A, Cantini G, Tani A et al (2017) Sodium-dependent glucose transporters (SGLT) in human ischemic heart: a new potential pharmacological target. Int J Cardiol 243:86\u201390. https:\/\/doi.org\/10.1016\/j.ijcard.2017.05.032","journal-title":"Int J Cardiol"},{"issue":"1","key":"5359_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12933-020-01141-1","volume":"19","author":"AA Sayour","year":"2020","unstructured":"Sayour AA, Olah A, Ruppert M et al (2020) Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure. Cardiovasc Diabetol 19(1):159. https:\/\/doi.org\/10.1186\/s12933-020-01141-1","journal-title":"Cardiovasc Diabetol"},{"issue":"10","key":"5359_CR25","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV (2018) SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 61(10):2108\u20132117. https:\/\/doi.org\/10.1007\/s00125-018-4670-7","journal-title":"Diabetologia"},{"issue":"4","key":"5359_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jacc.2019.11.036","volume":"75","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Braunwald E (2020) Clinical benefit of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review. J Am Coll Cardiol 75(4):435\u2013447. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.036","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"5359_CR27","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00395-018-0696-8","volume":"113","author":"HE Botker","year":"2018","unstructured":"Botker HE, Hausenloy D, Andreadou I et al (2018) Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol 113(5):39. https:\/\/doi.org\/10.1007\/s00395-018-0696-8","journal-title":"Basic Res Cardiol"},{"issue":"3","key":"5359_CR28","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/cvr\/cvw219","volume":"113","author":"DI Bromage","year":"2017","unstructured":"Bromage DI, Pickard JM, Rossello X et al (2017) Remote ischaemic conditioning reduces infarct size in animal in vivo models of ischaemia-reperfusion injury: a systematic review and meta-analysis. Cardiovasc Res 113(3):288\u2013297. https:\/\/doi.org\/10.1093\/cvr\/cvw219","journal-title":"Cardiovasc Res"},{"issue":"7","key":"5359_CR29","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6(7):e1000097. https:\/\/doi.org\/10.1371\/journal.pmed.1000097","journal-title":"PLoS Med"},{"issue":"6","key":"5359_CR30","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/sj.jcbfm.9600064","volume":"25","author":"MR Macleod","year":"2005","unstructured":"Macleod MR, O\u2019Collins T, Horky LL, Howells DW, Donnan GA (2005) Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab 25(6):713\u2013721. https:\/\/doi.org\/10.1038\/sj.jcbfm.9600064","journal-title":"J Cereb Blood Flow Metab"},{"key":"5359_CR31","unstructured":"Higgins JPT, Thomas J, Chandler J et al (eds) (2020) Cochrane handbook for systematic reviews of interventions version 6.1 [updated September 2020]. Available from www.training.Cochrane.org\/handbook. Accessed 25 Sept 2020"},{"issue":"5","key":"5359_CR32","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/jcbfm.2014.28","volume":"34","author":"ES Sena","year":"2014","unstructured":"Sena ES, Currie GL, McCann SK, Macleod MR, Howells DW (2014) Systematic reviews and meta-analysis of preclinical studies: why perform them and how to appraise them critically. J Cereb Blood Flow Metab 34(5):737\u2013742. https:\/\/doi.org\/10.1038\/jcbfm.2014.28","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3","key":"5359_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36(3):1\u201348","journal-title":"J Stat Softw"},{"issue":"Pt 3","key":"5359_CR34","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1348\/000711010X502733","volume":"63","author":"AP Field","year":"2010","unstructured":"Field AP, Gillett R (2010) How to do a meta-analysis. Br J Math Stat Psychol 63(Pt 3):665\u2013694. https:\/\/doi.org\/10.1348\/000711010X502733","journal-title":"Br J Math Stat Psychol"},{"issue":"4","key":"5359_CR35","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1037\/1082-989X.10.4.428","volume":"10","author":"JL Vevea","year":"2005","unstructured":"Vevea JL, Woods CM (2005) Publication bias in research synthesis: sensitivity analysis using a priori weight functions. Psychol Methods 10(4):428\u2013443. https:\/\/doi.org\/10.1037\/1082-989X.10.4.428","journal-title":"Psychol Methods"},{"issue":"8","key":"5359_CR36","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jacc.2004.06.071","volume":"44","author":"RJ Gibbons","year":"2004","unstructured":"Gibbons RJ, Valeti US, Araoz PA, Jaffe AS (2004) The quantification of infarct size. J Am Coll Cardiol 44(8):1533\u20131542. https:\/\/doi.org\/10.1016\/j.jacc.2004.06.071","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"5359_CR37","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1161\/CIRCRESAHA.117.310820","volume":"120","author":"G Heusch","year":"2017","unstructured":"Heusch G (2017) Critical issues for the translation of cardioprotection. Circ Res 120(9):1477\u20131486. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.310820","journal-title":"Circ Res"},{"issue":"3","key":"5359_CR38","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B et al (2018) Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation. Diabetologia 61(3):722\u2013726. https:\/\/doi.org\/10.1007\/s00125-017-4509-7","journal-title":"Diabetologia"},{"issue":"7","key":"5359_CR39","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E (2016) CV protection in the EMPA-REG OUTCOME trial: a \u201cThrifty Substrate\u201d hypothesis. Diabetes Care 39(7):1108\u20131114. https:\/\/doi.org\/10.2337\/dc16-0330","journal-title":"Diabetes Care"},{"issue":"7","key":"5359_CR40","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/cvr\/cvz050","volume":"115","author":"I Andreadou","year":"2019","unstructured":"Andreadou I, Cabrera-Fuentes HA, Devaux Y et al (2019) Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. Cardiovasc Res 115(7):1117\u20131130. https:\/\/doi.org\/10.1093\/cvr\/cvz050","journal-title":"Cardiovasc Res"},{"issue":"7","key":"5359_CR41","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1093\/cvr\/cvy304","volume":"115","author":"CJ Zuurbier","year":"2019","unstructured":"Zuurbier CJ, Abbate A, Cabrera-Fuentes HA et al (2019) Innate immunity as a target for acute cardioprotection. Cardiovasc Res 115(7):1131\u20131142. https:\/\/doi.org\/10.1093\/cvr\/cvy304","journal-title":"Cardiovasc Res"},{"issue":"6","key":"5359_CR42","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s00395-017-0653-y","volume":"112","author":"MV Cohen","year":"2017","unstructured":"Cohen MV, Downey JM (2017) The impact of irreproducibility and competing protection from P2Y12 antagonists on the discovery of cardioprotective interventions. Basic Res Cardiol 112(6):64. https:\/\/doi.org\/10.1007\/s00395-017-0653-y","journal-title":"Basic Res Cardiol"},{"issue":"1","key":"5359_CR43","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","volume":"11","author":"SR Kim","year":"2020","unstructured":"Kim SR, Lee SG, Kim SH et al (2020) SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun 11(1):2127. https:\/\/doi.org\/10.1038\/s41467-020-15983-6","journal-title":"Nat Commun"},{"issue":"1","key":"5359_CR44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12933-020-01016-5","volume":"19","author":"V Spigoni","year":"2020","unstructured":"Spigoni V, Fantuzzi F, Carubbi C et al (2020) Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events. Cardiovasc Diabetol 19(1):46. https:\/\/doi.org\/10.1186\/s12933-020-01016-5","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"5359_CR45","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1177\/1074248412467692","volume":"18","author":"XM Yang","year":"2013","unstructured":"Yang XM, Liu Y, Cui L et al (2013) Platelet P2Y(1)(2) blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther 18(3):251\u2013262. https:\/\/doi.org\/10.1177\/1074248412467692","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"6","key":"5359_CR46","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S2213-8587(17)30314-5","volume":"6","author":"RM Bell","year":"2018","unstructured":"Bell RM, Yellon DM (2018) SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection. Lancet Diabetes Endocrinol 6(6):435\u2013437. https:\/\/doi.org\/10.1016\/S2213-8587(17)30314-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"5359_CR47","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/j.jacc.2018.06.040","volume":"72","author":"TA Zelniker","year":"2018","unstructured":"Zelniker TA, Braunwald E (2018) Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol 72(15):1845\u20131855. https:\/\/doi.org\/10.1016\/j.jacc.2018.06.040","journal-title":"J Am Coll Cardiol"},{"key":"5359_CR48","doi-asserted-by":"publisher","unstructured":"Zuurbier CJ, Keijzers PJ, Koeman A, Van Wezel HB, Hollmann MW (2008) Anesthesia\u2019s effects on plasma glucose and insulin and cardiac hexokinase at similar hemodynamics and without major surgical stress in fed rats. Anesth Analg 106(1):135\u2013142. https:\/\/doi.org\/10.1213\/01.ane.0000297299.91527.74","DOI":"10.1213\/01.ane.0000297299.91527.74"},{"key":"5359_CR49","doi-asserted-by":"publisher","unstructured":"Penna C, Andreadou I, Aragno M et al (2020) Effect of hyperglycaemia and diabetes on acute myocardial ischaemia-reperfusion injury and cardioprotection by ischaemic conditioning protocols. Br J Pharmacol. https:\/\/doi.org\/10.1111\/bph.14993","DOI":"10.1111\/bph.14993"},{"issue":"10254","key":"5359_CR50","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","volume":"396","author":"F Zannad","year":"2020","unstructured":"Zannad F, Ferreira JP, Pocock SJ et al (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396(10254):819\u2013829. https:\/\/doi.org\/10.1016\/S0140-6736(20)31824-9","journal-title":"Lancet"},{"issue":"1","key":"5359_CR51","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1124\/jpet.116.232025","volume":"358","author":"R Ohgaki","year":"2016","unstructured":"Ohgaki R, Wei L, Yamada K et al (2016) Interaction of the sodium\/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2. J Pharmacol Exp Ther 358(1):94\u2013102. https:\/\/doi.org\/10.1124\/jpet.116.232025","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"5359_CR52","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/cvr\/cvz037","volume":"115","author":"Z Li","year":"2019","unstructured":"Li Z, Agrawal V, Ramratnam M et al (2019) Cardiac sodium-dependent glucose cotransporter 1 is a novel mediator of ischaemia\/reperfusion injury. Cardiovasc Res 115(11):1646\u20131658. https:\/\/doi.org\/10.1093\/cvr\/cvz037","journal-title":"Cardiovasc Res"},{"issue":"6","key":"5359_CR53","doi-asserted-by":"publisher","first-page":"F1201","DOI":"10.1152\/ajprenal.00111.2019","volume":"316","author":"J Nespoux","year":"2019","unstructured":"Nespoux J, Patel R, Hudkins KL et al (2019) Gene deletion of the Na(+)-glucose cotransporter SGLT1 ameliorates kidney recovery in a murine model of acute kidney injury induced by ischemia-reperfusion. Am J Physiol Renal Physiol 316(6):F1201\u2013F1210. https:\/\/doi.org\/10.1152\/ajprenal.00111.2019","journal-title":"Am J Physiol Renal Physiol"},{"issue":"4","key":"5359_CR54","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1161\/CIRCRESAHA.116.305348","volume":"116","author":"G Heusch","year":"2015","unstructured":"Heusch G (2015) Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res 116(4):674\u2013699. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.305348","journal-title":"Circ Res"},{"issue":"1","key":"5359_CR55","doi-asserted-by":"publisher","first-page":"e012940","DOI":"10.1161\/JAHA.119.012940","volume":"9","author":"V Raparelli","year":"2020","unstructured":"Raparelli V, Elharram M, Moura CS et al (2020) Sex differences in cardiovascular effectiveness of newer glucose-lowering drugs added to metformin in type 2 diabetes mellitus. J Am Heart Assoc 9(1):e012940. https:\/\/doi.org\/10.1161\/JAHA.119.012940","journal-title":"J Am Heart Assoc"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-020-05359-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-020-05359-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-020-05359-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T11:09:12Z","timestamp":1615201752000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-020-05359-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,23]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["5359"],"URL":"https:\/\/doi.org\/10.1007\/s00125-020-05359-2","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,23]]},"assertion":[{"value":"23 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}